| Abstrakt: |
Ampullary carcinomas, a rare form of cancer, are increasing in incidence. Researchers from the University of Wisconsin School of Medicine and Public Health have found that ampullary cancers have molecular alterations that can guide therapy choices, especially in nonresectable cases. They recommend next-generation sequencing for patients who cannot undergo surgery. This article reviews the approach to tissue acquisition and molecular testing for ampullary cancer, discussing common molecular targets such as HER2/ERBB2, HER3, KRAS, and germline BRCA and ATM mutations, as well as emerging and rarer alterations. [Extracted from the article] |
